Find a Clinical Trial | Tufts Medicine

Filter

Showing 1 - 10 out of 19

AEROVATE Extension

A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002 (IMPAHCT-FUL)

Interstitial lung diseases, Pulmonary hypertension

All genders

18-75

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Learn more

CADENCE Study

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)

Heart failure, Pulmonary hypertension

All genders

18-85

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Learn more

A Phase 2, Open-Label, Dose Escalation Study to Evaluate the Safety and Efficacy of RT234

A Phase 2, Open-Label, Dose Escalation Study to Evaluate the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects with Pulmonary Arterial Hypertension (PAH)

Pulmonary hypertension

All genders

18-80

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Learn more

Insmed TPIP Study

A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Interstitial lung diseases, Pulmonary hypertension

All genders

18-75

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Learn more

Daewoong IPF study

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis

Pulmonary fibrosis

All genders

40-100

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Learn more

Tenax Phase 3: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

A Phase 3, Double-Blind, Randomized, Placebo-Controlled
Study of Levosimendan in Pulmonary Hypertension Patients
With Heart Failure With Preserved Left Ventricular Ejection
Fraction (PH-HFpEF); LEVEL: LEVosimendan to Improve
Exercise Limitation in Patients With PH-HFpEF

All genders

18+

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Learn more

INSPiRE-ICU 1

A Phase 3, Multicenter, Randomized, Controlled, Open Label, Assessor-Blinded Study to Evaluate the Efficacy and Safety of Inhaled Isoflurane Delivered via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU 1)

Intensive care

All genders

18+

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Learn more

A Phase 3 Study of Sotatercept for the Treatment of PAH

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH

Pulmonary hypertension

All genders

18-18

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Learn more

A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk PAH Patients

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients

Pulmonary hypertension

All genders

18+

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Learn more

A Phase 3 Study of Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk of Mortality

Pulmonary hypertension

All genders

18-75

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Learn more